BRD9 and metabolic dysfunction-associated steatotic liver disease: These findings suggest that BRD9 negatively regulates PPARα-mediated lipid metabolism, and its inhibition could be a novel therapeutic strategy for treating dyslipidemia, MASLD, and MASH.